BCL2 (B-cell CLL/lymphoma 2)

Cochlospermum religiosum exhibits promising multitarget anticancer potential, coupled with immunomodulatory and hepatoprotective effects. These findings provide a strong foundation for further mechanistic and clinical investigations.

Antioxidant assays reveal a DPPH•-scavenging IC₅₀ of 25 µg mL⁻¹ lower than any green-synthesised MgO reported to date. Comprehensive GC-MS, FT-IR and time-resolved XRD tracking link the vacancy stabilization and ripening inhibition to the coordinated gallic-acid/flavolipid corona.

SwissADME analysis indicated favorable drug-likeness properties. This work demonstrates the value of a natural product-inspired scaffold-hopping strategy in identifying promising new anticancer molecules with important pharmacological properties.

These findings support the hypothesis that volatile anesthetics may reduce short-term recurrence risk and warrant larger, longer-term trials to validate oncological outcomes.

Energy decomposition analysis suggested that complex stabilization is primarily driven by shape complementarity and hydrophobic effects, rather than conventional hydrogen bonding or salt bridges. Conclusion This study reveals that the antitumor activity of Baicalein is mediated through its multi-target action on core components of the PI3K-AKT pathway, thereby offering novel insights for exploring its therapeutic targets.

Flow cytometry revealed G0/G1 cell cycle arrest, with downregulation of Cyclin D1 and CDK4 and upregulation of p21 and p27. These findings indicate that Sa-EAE exerts dual effects of mitochondrial-mediated apoptosis and G0/G1 arrest in gastric cancer cells, with minimal toxicity to normal cells, supporting its potential as a therapeutic candidate for further in vivo validation.

In biochemical assays, H5 shows IC50 = 7.9 ± 0.5 nM, outperforming JQ-1 (IC50 = 33.0 ± 1.0 nM) by 4-fold...In the HCT-116 xenograft mouse model, oral administration of H5 suppressed tumor growth (TGI = 82 % at 50 mg/kg) and downregulated the BRD4-driven oncoproteins c-MYC and BCL-2. Collectively, H5 emerges as a highly promising BRD4-targeted candidate for colorectal cancer treatment.

Kaplan-Meier analysis of R-CHOP-treated patients with DLBCL-NOS revealed that those with MCD, BN2, and A53 subtypes had poorer overall survival than those with EZB and ST2, particularly among patients with concurrent MYC/BCL2 DE. Using a clinically applicable NGS panel, we successfully implemented the LymphGen classification system. This study underscores the distinct genetic landscape of Korean DLBCL and highlights the utility of LymphGen in identifying high-risk subgroups, providing a basis for prognostic stratification and therapeutic optimization.

LIF/LIFR protein accumulated from 2-72 h (48 h apex). These time-resolved data reveal progressive oedema with sustained oxidative burden and a LIF-JAK1-STAT3 activation peak, suggesting a therapeutic window in AHH-induced retinal injury.

Western blot results further indicated that TA treatment increased the expression of Bax while decreasing the expression levels of PI3K, AKT, HSP90, and Bcl-2. TA suppressed the proliferation of HepG2 cells and induced apoptosis, possibly by regulating the PI3K/AKT/HSP90 signaling pathway.

Pathway and perturbation analyses suggested that NCI-LYM-1 harbored a strong dependency on apoptotic pathways, which was confirmed by in vitro organoid testing with the BCL-2/BCL-xL inhibitor navitoclax (IC 50 : 0.27 µM) and the MCL-1 inhibitor AZD-5991 (IC 50 : 0.060 µM). Overall, NCI-LYM-1 recapitulates the clinical aggressiveness and heterogeneity of AVPC, providing a tractable platform to identify novel precision therapies.

The increased abundance of L. reuteri and L. murinus was associated with regulated cellular proliferation, reduced TNF-α production, and decreased expression of COX-2, cyclin D1, and Bcl-2. In conclusion, the results obtained signify the nutraceutical potential of phloretin in restoring the intestinal barrier, maintaining the beneficial gut microbial population, and amelioration of CAC in mice.